COVID-19 patients who also suffer from high blood pressure are more likely to fall severely ill, which also leaves them at greater risk of death. Scientists from the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin, with partners in Heidelberg and Leipzig, have now found that the immune cells of patients with hypertension are already pre-activated, and that this is greatly enhanced under COVID-19. However, certain hypertension-reducing drugs known as ACE inhibitors can have a beneficial effect. They not only lower blood pressure, but also counteract immune hyperactivation. The scientists have now published their findings in the journal Nature Biotechnology.